
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is a promising biotech company with a focus on precision medicine for oncology patients. The company's strong pipeline of clinical-stage product candidates shows potential for targeted therapies in multiple patient populations. Their positive clinical trial data and potential for off-label use in HLA-A*02:01-positive mUM, along with a planned NDA submission and potential US launch in 2027, make them a strong investment opportunity. Additionally, the company's strong safety and tolerability profile, as well as its potential for significant revenue growth, further support a positive outlook for the stock.
Bears say
IDEAYA Biosciences is facing potential key risks including disappointing PFS readouts for darovasertib, challenged market opportunities in neo-adjuvant UM, and uncertainty around commercialization for pipeline programs. Additionally, despite the excitement from KOLs and potential for treating past progression, the company's estimated average treatment duration of 7 months may be conservative, limiting potential revenue. Therefore, the analyst has a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares